arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

KYNTRA BIO, INC.

KYNB
$3.72 ▼ -0.40 (-9.82%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
14 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
30
Health
Poor
Bullish
auto_awesome

Analytical Summary

KYNTRA BIO, INC. shows strong fundamentals with top-quartile Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $15.0M
Dividend Yield —
Revenue Growth -78.3% ↗
Op. Margin None
ROIC -101.9% ↘
FCF / Share $-1.19 ↗
Trailing P/E 0.1x
Price / Book —
FCF Yield —
Debt / Equity -2.50
info Valuation on last close. End-of-day price, Nov 5, 2026.

14-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$6.44M
↓ -78.3% —
Net Income Profit after all expenses
$183.45M
↑ +485.6% —
Operating Margin Operating profit as % of sales
-190.7%
↑ +10.8% —
FCF / Share Free cash flow per share
$-1.19
↑ +96.6% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Profitability ↓
3
Financial Health ↑
68
Cash Quality
21

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 14 years · 52 quarters